| Huang, Yuan |
NCT05115942: Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Viral Hepatitis B Phase 3 Trial. |
|
|
| Completed | 3 | 248 | RoW | Hydronidone capsules, F351, The placebo capsules, N | Beijing Continent Pharmaceutical Co, Ltd. | Liver Fibrosis | 10/24 | 10/24 | | |
NCT05905172: Hydronidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver Fibrosis |
|
|
| Recruiting | 3 | 248 | RoW | Hydronidone capsules, F351, The placebo capsules, N | Beijing Continent Pharmaceutical Co, Ltd. | Liver Fibrosis | 06/28 | 10/28 | | |
| Yang, Ming |
NCT06057571: Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor |
|
|
| Recruiting | 2 | 50 | RoW | TT-00420 (tinengotinib) | TransThera Sciences (Nanjing), Inc. | Cholangiocarcinoma Metastatic | 06/25 | 10/25 | | |
| Recruiting | 1/2 | 103 | RoW | TQB2102 for injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Biliary Tract Cancer | 05/25 | 12/25 | | |
NCT05668403: A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy |
|
|
| Recruiting | 1 | 52 | RoW | B007 | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Primary Membranous Nephropathy | 12/24 | 12/24 | | |
NCT04953936: β-hydroxy-β-methylbutyrate-enriched Nutritional Supplements for Obesity Adults |
|
|
| Not yet recruiting | N/A | 72 | RoW | HMB-enriched Nutritional Supplements, Placebo, Caloric Restrition Diet | West China Hospital | Obesity | 10/21 | 12/21 | | |
| Recruiting | N/A | 600 | Canada | Implementation of WAPPS-Hemo personalized dosing regimen | McMaster University | Hemophilia A, Hemophilia B | 09/22 | 09/23 | | |
| Recruiting | N/A | 40 | RoW | Pennisetum purpureum, Placebo | Taipei Medical University | Sarcopenia | 03/24 | 03/24 | | |
